Status:
ACTIVE_NOT_RECRUITING
A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors
Lead Sponsor:
Tallac Therapeutics
Conditions:
Advanced or Metastatic Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
INCLINE-101 is an open label, multicenter Phase 1/2 study designed to evaluate safety, pharmacokinetics (PK), and preliminary anti-tumor activity of TAC-001 administered intravenously.
Eligibility Criteria
Inclusion
- Histologically or cytologically-documented solid tumors.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.
- Demonstrate adequate organ function.
Exclusion
- Prior history of or active malignant disease other than that being treated in this study.
- Known brain metastases or cranial epidural disease.
- A known hypersensitivity to the components of the study therapy or its' analogs.
Key Trial Info
Start Date :
June 28 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 19 2026
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT05399654
Start Date
June 28 2022
End Date
May 19 2026
Last Update
August 16 2024
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Southern California (USC)
Los Angeles, California, United States, 90033
2
University of Colorado
Aurora, Colorado, United States, 80045
3
Sarah Cannon Research Institute (SCRI)- Denver
Denver, Colorado, United States, 80218
4
AdventHealth Cancer Institute
Orlando, Florida, United States, 32804